Literature DB >> 33216971

Pityriasis rosea-like eruption revealing COVID-19.

Stefano Veraldi1, Maurizio Romagnuolo1,2, Valentina Benzecry1,2.   

Abstract

Entities:  

Year:  2020        PMID: 33216971      PMCID: PMC7753512          DOI: 10.1111/ajd.13504

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


× No keyword cloud information.
Dear Editor, Pityriasis rosea is an acute, exanthematous disease likely caused by human herpesvirus HHV‐6 and/or HHV‐7. , It mainly affects young adults. We present two cases of pityriasis rosea‐like eruptions associated with COVID‐19 infection. A 26‐year‐old man was admitted with a diagnosis of pityriasis rosea. The patient was in good general health and was not on therapy with systemic drugs. He stated that the rash appeared some days earlier and was accompanied by pruritus. He also complained of mild headache, weakness and arthralgia. Dermatological examination revealed several erythematous‐squamous papules and plaques located mainly on the upper limbs and trunk (Fig. 1). A diagnosis of pityriasis rosea‐like eruption was made. Laboratory tests (including complete blood cell, liver and renal function, inflammatory markers, syphilis serology) showed only slight increase of erythrocyte sedimentation rate. Nasal swab was positive for SARS‐CoV‐2. Chest X‐ray was normal. Cetirizine (10 mg/day) was prescribed. The patient was followed at his home. Skin lesions and other symptoms resolved within three weeks.
Figure 1

Patient 1. Several erythematous‐squamous papules and plaques located on the upper limbs and back.

Patient 1. Several erythematous‐squamous papules and plaques located on the upper limbs and back. A 21‐year‐old man was admitted because of the appearance of a single infiltrated, erythematous, oval lesion located on the left hip (Fig. 2a). Mycological examination was negative. A diagnosis of herald patch of pityriasis rosea was made. No treatment was suggested. One week later, the patient returned with a widespread erythematous‐squamous rash on the chest and back, with lesions of different morphology and size (Fig. 2b). The patient complained of pruritus. Furthermore, the patient reported anorexia, abdominal pain, diarrhoea and weakness. We performed nasal swab for SARS‐CoV‐2, which was positive. All the other laboratory examinations were within normal ranges or negative. Also, this patient was followed at home and treated with cetirizine (10 mg/day). Both the rash and symptoms subsided within three weeks.
Figure 2

Patient 2. (a) Herald patch. (b) Widespread erythematous‐squamous rash on the chest, with lesions of different morphology and size.

Patient 2. (a) Herald patch. (b) Widespread erythematous‐squamous rash on the chest, with lesions of different morphology and size. Various cutaneous manifestations have been associated with COVID‐19. , In addition to our cases, one other case of a pityriasis rosea‐like eruption has also been reported. The cases we have described show a temporal relationship between pityriasis rosea or pityriasis rosea‐like eruption and COVID‐19, but they do not prove causality.
  10 in total

1.  COVID-19-associated pityriasis rosea in children: Case report and literature review.

Authors:  Maryam Khalili; Bahareh Abtahi-Naeini; Fereshte Rastegarnasab; Kimia Afshar
Journal:  Clin Case Rep       Date:  2022-07-19

2.  Pityriasis rosea infection in a COVID-19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS-CoV-2 infection.

Authors:  Giovanni Paolino; Matteo Riccardo Di Nicola; Carmen Cantisani; Santo Raffaele Mercuri
Journal:  Dermatol Ther       Date:  2021-05-24       Impact factor: 3.858

3.  An Observational Study of Mucocutaneous Manifestations among SARS-CoV-2 Patients from Three COVID-19 Dedicated Tertiary Care Centers.

Authors:  Alpana Mohta; Achala Mohta; Radhe Shyam Nai; Aakanksha Arora; Suresh Kumar Jain; Alok Mohta; Rajesh Dutt Mehta; Bhikam Chand Ghiya; Vijeta Prasad; Rajesh Khokhar; Rajat Toteja; Gaurav Bha Rgava
Journal:  Indian Dermatol Online J       Date:  2021-09-10

Review 4.  COVID-19 Skin Manifestations in Skin of Colour.

Authors:  Edgar Akuffo-Addo; Mathew N Nicholas; Marissa Joseph
Journal:  J Cutan Med Surg       Date:  2021-10-19       Impact factor: 2.092

Review 5.  SARS-CoV-2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?

Authors:  Jungang Chen; Jiao Song; Lu Dai; Steven R Post; Zhiqiang Qin
Journal:  J Med Virol       Date:  2022-07-22       Impact factor: 20.693

Review 6.  Pathobiology of Cutaneous Manifestations Associated with COVID-19 and Their Management.

Authors:  Waniyah Masood; Shahzaib Ahmad; Noor Ayman Khan; Amaima Shakir; Ghasem Rahmatpour Rokni; Michael H Gold; Clay J Cockerell; Robert A Schwartz; Mohamad Goldust
Journal:  Viruses       Date:  2022-09-06       Impact factor: 5.818

7.  Cutaneous Eruptions in the Course of COVID-19 Among Geriatric Patients in a Nursing Home in Poland.

Authors:  Joanna Rybak-d'Obyrn; Waldemar Placek; Agnieszka Owczarczyk-Saczonek; Maria Derkaczew; Ewelina Joniec; Robert Hofman; Małgorzata Stompór
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-10-04

Review 8.  Skin disorders associated with the COVID-19 pandemic: A review.

Authors:  Jennifer Akl; Jessica El-Kehdy; Antoine Salloum; Anthony Benedetto; Paula Karam
Journal:  J Cosmet Dermatol       Date:  2021-07-01       Impact factor: 2.189

Review 9.  Skin manifestations in patients with coronavirus disease 2019.

Authors:  Matteo Bassetti; Cesare Massone; Antonio Vena; Silvia Dettori; Claudio Conforti; Daniele Roberto Giacobbe; Iris Zalaudek
Journal:  Curr Opin Infect Dis       Date:  2022-04-01       Impact factor: 4.915

10.  Pityriasis rosea and COVID-19.

Authors:  Stefano Veraldi; Cristina B Spigariolo
Journal:  J Med Virol       Date:  2020-12-01       Impact factor: 20.693

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.